secwatch.observer — SEC 8-K summary
======================================

Issuer:     MeiraGTx Holdings plc (MGTX)
CIK:        0001735438
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0001558370-24-011797
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MeiraGTx reports Q2 net loss of $48.6M and $50M offering led by Sanofi
----------------------------------------------------------------------

- Net loss $48.6M ($0.76/share) vs $29.6M ($0.53) in Q2 2023; service revenue $0.3M, no license revenue.
- Offering of 12.5M shares at $4.00 each for $50M gross proceeds; led by Sanofi ($30M) with Perceptive Advisors.
- Cash and equivalents $100.0M as of June 30, 2024; believes funded into Q2 2026 with $285M potential J&J milestones.
- Phase 2 AQUAx2 for xerostomia enrolling; FDA aligned on pivotal trial design. AAV-GAD for Parkinson's results expected Q4 2024.
- UK ILAP designation for AAV-AIPL1 in LCA4; all 11 treated blind children gained visual acuity. Riboswitch platform data later 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1735438/000155837024011797/0001558370-24-011797-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1735438/000155837024011797/mgtx-20240812x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-011797

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer